Others demonstrated that small molecule inhibitors of GSK3β affected the viability and transformation capabilities of an ARMS tumor cell line.19 However, the first study utilized a general mutation approach that altered several serine residues within a region without specifically targeting the known sites, whereas the second study failed to demonstrate that the small molecule inhibitors directly altered phosphorylation of PAX3-FOXO1. The gene discussed is PAX3; the disease is neoplasm.